Tepmetko 225 mg (Tepotinib (Tepotinib Hydrochloride) TABLET) 225 MG

TEPMETKO 225 MG is a medication containing tepotinib hydrochloride, used for targeted therapy. This oral tablet is designed to address specific health conditions, offering a precise approach to treatment.

Strength

225 MG

Manufacturer / TM Owner

EMD SERONO, A DIVISION OF EMD INC., CANADA

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

TEPMETKO 225 MG is primarily used in targeted therapy to address certain health conditions. Tepotinib, the active ingredient, is designed to interact with specific proteins involved in cell growth and division. This medication is often explored for its potential in managing conditions related to abnormal cell proliferation, though individual responses may vary.

Side Effects

Common effects of TEPMETKO 225 MG may include gastrointestinal discomfort, fatigue, and skin reactions. Some users might experience changes in appetite or mild dizziness. These effects are generally mild and temporary, but consulting a healthcare provider is advisable if they persist or worsen.

Precautions & Warnings

TEPMETKO 225 MG should be handled with care, following the guidance of a healthcare professional. It is important to disclose any existing medical conditions or allergies before starting this medication. Regular monitoring may be recommended to ensure safety and efficacy.

Avoid Interactions

TEPMETKO 225 MG may interact with certain medications, including those metabolized by the liver's CYP enzymes. Alcohol consumption should be avoided as it may exacerbate side effects. Always inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.

Frequently Asked Questions

TEPMETKO 225 MG is used in targeted therapy to address specific health conditions related to abnormal cell growth.

TEPMETKO 225 MG is taken orally, typically as directed by a healthcare provider.

Common side effects may include gastrointestinal discomfort, fatigue, and skin reactions.

Potential interactions with other medications should be discussed with a healthcare provider.

Long-term use should be monitored by a healthcare provider to ensure safety and efficacy.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.